| Clinical data | |
|---|---|
| Other names | Erbuzole |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C24H27N3O5S |
| Molar mass | 469.56 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Erbulozole (R55104) is a congener of the microtubule inhibitor tubulozole. It is undergoing phase I clinical trials as a chemotherapeutic agent.

| CI monoclonal antibodies ("-mab") |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Tyrosine kinase inhibitors ("-nib") |
| ||||||||
| Other |
| ||||||||
This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by adding missing information. |